Prelude Therapeutics Announces CMO Departure, Appoints Interim
Ticker: PRLD · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1678660
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Prelude Therapeutics' CMO is out, interim CMO in. Consulting gig for the departing doc.
AI Summary
On October 15, 2025, Prelude Therapeutics Incorporated announced the departure of Dr. Christopher V. Fountas as Chief Medical Officer. The company also announced the appointment of Dr. Sara M. Kenkare-Pande as interim Chief Medical Officer. Dr. Fountas will transition to a consulting role to ensure a smooth handover.
Why It Matters
A change in key executive leadership, especially the Chief Medical Officer, can impact a pharmaceutical company's strategic direction and clinical development pipeline.
Risk Assessment
Risk Level: medium — Changes in executive leadership, particularly in critical roles like CMO, can introduce uncertainty regarding the company's strategic direction and execution of its clinical programs.
Key Players & Entities
- Prelude Therapeutics Incorporated (company) — Registrant
- Dr. Christopher V. Fountas (person) — Departing Chief Medical Officer
- Dr. Sara M. Kenkare-Pande (person) — Interim Chief Medical Officer
- October 15, 2025 (date) — Date of earliest event reported
FAQ
What is the effective date of Dr. Christopher V. Fountas's departure as Chief Medical Officer?
The filing indicates that the earliest event reported is October 15, 2025, which is the date of the report concerning the departure.
Who has been appointed as the interim Chief Medical Officer for Prelude Therapeutics?
Dr. Sara M. Kenkare-Pande has been appointed as the interim Chief Medical Officer.
Will Dr. Christopher V. Fountas continue to be involved with Prelude Therapeutics in any capacity?
Yes, Dr. Fountas will transition to a consulting role to ensure a smooth handover.
What is the primary business of Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated is in the Pharmaceutical Preparations industry, SIC code 2834.
In which state was Prelude Therapeutics Incorporated incorporated?
Prelude Therapeutics Incorporated was incorporated in Delaware.
Filing Stats: 1,020 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2025-10-17 07:40:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PRLD Nasdaq Glo
Filing Documents
- prld-20251015.htm (8-K) — 56KB
- prld-ex99_1.htm (EX-99.1) — 24KB
- img268059179_0.jpg (GRAPHIC) — 19KB
- 0001193125-25-241968.txt ( ) — 241KB
- prld-20251015.xsd (EX-101.SCH) — 44KB
- prld-20251015_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 17, 2025, the Company issued a press release announcing the appointment of Ms. Dorton to the Board. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished, but shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Exhibit Number Description 99.1 Press release announcing the appointment of Katina Dorton, dated October 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRELUDE THERAPEUTICS INCORPORATED Date: October 17, 2025 By: / s/ Bryant Lim Bryant Lim Chief Legal Officer, Corporate Secretary, and Chief Financial Officer